High quality medical services for marginalized groups in Cairo and the region.

Mersal Foundation for Charity and Development is a non-profit organization that serves in the health field and works on providing all types of healthcare with high quality to whoever is in need.

**Vision**
To be the number one medical organization in Egypt and the Arab region and proactive in ensuring the right in healthcare for the marginalized groups and those who are in need the most.

**Message**
Working on analyzing and filling the gaps of the healthcare system to provide high quality medical services on the basis of equality and dignity through enabling a charitable healthcare system for whoever cannot afford it, as well as contributing to the development of the health sector.

**Objectives**  

- Providing medical services to whoever deserves them regardless the cost or for how long they will be needed.
- Spreading medical awareness in all the places it serves in.
- Achieving sustainability in funding its activities Core Values.
- Privacy: Mersal ensures the patient's eligibility to receive its services without hurting their dignity or exposing them to any kind of embarrassment.
- Healthcare With No Discrimination: Mersal is an open arm to all patients with no discrimination whatsover; whatever religion, nationality, color, or language, all patients in need are welcomed to receive the organization services.
- High Quality: Mersal provides all types of medical services in the highest possible quality through its network of specialized medical personnel.
- Credibility and Transparency: Mersal announces the size and sources of its fund as well as its administrative and medical expenditures, The foundation financial reports and annual budgets are available through several outlets through which any person can explore how resources are managed. Mersal believes in the importance of being specialized in specific fields and its early choice was the healthcare services.

In the past six years, the organization registered over 25,000 patients from 27 provinces.  Mersal has been seeking to enable access to its services all over the country. And the dream of helping those who are in need whoever they are and whatever the cost and time is still alive, Mersal has worked over the past six years on getting close to its patients throughout their treatment journey.

Mersal Foundation for Charity and Development 

Not for profit, founded as a 501C3 charity in 2006 in NYC. Providing Health, Education, and Empowerment opportunities.

Our cornerstone project was building East & Central Africa's 1st Public Children's Hospital.  Since opening in 2015, we have treated over 1.3 million kids. The impact does not end there, we have also constructed six public (free-to-attend) schools, a dairy project, a kids community house and more. We also run a vibrant Women's Empowerment Project focusing on agri-biz and domestic violence survivors.  Our latest major project is constructing the first children's cancer hospital in sub-Saharan Africa.

visit our Learn About Us page on shoe4africa.org

Shoe4Africa

We provide cash incentives for childhood vaccinations. It’s one of the most cost-effective ways known to save lives.


New Incentives’ mission is to save lives in a way that does the **most good per dollar**.
Guided by evidence, we provide cash incentives to increase childhood vaccination rates.

- We [raise awareness](https://www.newincentives.org/blog-posts/awareness-activities) about the benefits of childhood vaccinations.
- We [provide cash incentives](https://www.newincentives.org/blog-posts/a-day-in-the-life-abubakar-aliyu-field-officer) at government clinics after children receive vaccinations.
- We [help improve the vaccine supply chain](https://www.newincentives.org/blog-posts/supporting-government-partners-with-vaccine-supply-efforts) to ensure enough vaccines are available at clinics.

Together, these efforts are proven to double vaccination rates and save lives.
Learn more about the [randomized controlled trial](https://www.newincentives.org/rct-results).

As of March 2024, New Incentives has reached more the 3 million infants in northern Nigeria.

New Incentives

Delivering medical aid where it's needed most — independent, neutral, impartial.

Doctors Without Borders/Médecins Sans Frontières (MSF) is an international medical humanitarian organization created by doctors and journalists in France in 1971.

In over 70 countries around the world, MSF saves lives by providing medical aid where it is needed most—in armed conflicts, epidemics, natural disasters, and other crises.  The people who work for MSF are doctors, nurses, midwives, epidemiologists, water-and-sanitation experts and many others who combine their professional expertise with a commitment to the world’s most vulnerable people.  Each year, these medical teams run close to 470 projects where they care for millions of people.  

As an organization, MSF is neutral and operates independently of any political, military, or religious agendas. It does not take sides in armed conflicts, provides care based on needs alone, and advocates for increased independent access to victims of conflict and disaster as required under international humanitarian law. Medical teams conduct evaluations on the ground to determine a population's medical needs before opening programs, aiming to fill gaps that exist (rather than replicating services that are already offered) or reach communities that are not being assisted.  Over the years, the organization has been the recipient of several awards that recognize its work, including the 1998 Conrad N. Hilton Humanitarian Prize, the 1999 Nobel Peace Prize, the 2012 J. William Fulbright Prize for International Understanding, the 2015 Lasker-Bloomberg Public Service Award, and the 2017 Pardes Humanitarian Prize for Mental Health.

Doctors Without Borders/Médecins Sans Frontières (MSF) 

We are a research hospital that treats patients in all medical disciplines, focusing on oncology, neurology, and diagnosis.

The Fondazione Casa Sollievo della Sofferenza – Opera di San Pio da Pietrelcina (transl. Home for the Relief of Suffering Foundation – Work of Saint Pio of Pietrelcina) is a not-for-profit research hospital located in the city of San Giovanni Rotondo (FG), in the Puglia Region, Southern Italy.
As per Canon 1303 §1 of the Code of Canon Law, it has public, canonical and civil legal personality; it is therefore subject to the supervision of the Holy See and, on its behalf, of the pro-tempore Cardinal Secretary of State. 
Many of the stages that have thus far marked the history of the Work of San Pio of Pietrelcina have been achieved thanks to the loving generosity of many benefactors who, sharing the mission indicated by San Pio da Pietrelcina, the relief of suffering, wanted to donate to his work.

HISTORY
The hospital was founded and inaugurated by Saint Pio of Pietrelcina on May 5, 1956 with a capacity of 250 beds. It took on the status of Provincial Hospital on 4 August 1971 and then of Regional General Hospital on 2 June 1980, thus becoming part of the Italian National Healthcare System. Since 16 July 1991, with a Decree of the Minister of Health and the Minister of University and Scientific Research, it has been a Research Hospital. Originally, the object of its scientific activity was limited to genetic and hereditary-familial diseases; subsequently, the Minister of Health, by the 5 December 2012 Decree, extended the research areas of its competence to "Genetic diseases, innovative therapies and regenerative medicine". Recently, on the occasion of the presentation of the research lines for the three-year programme of the Italian Research Hospitals 2022-2024, Casa Sollievo identified “Diagnostic acitivity, Neurology and Oncology” as its main research thematic areas, thus becoming a polythematic Research Hospital.

MISSION
The Foundation's mission is to provide health care and carry out research activities. In addition, the Foundation offers training activities for its personnel.
Around 2,750 people work at the Foundation.
The Foundation (hereinafter “CSS”) consists of three structures based in San Giovanni Rotondo: the hospital Casa Sollievo, the polyclinic Giovanni Paolo II, where outpatient activities are carried out, and the ISBReMIT research center for regenerative medicine (Institute for Stem-cell Biology, Regenerative Medicine and Innovative Therapies); and the Mendel Institute in Rome, where research and diagnostic activities are carried out. In San Giovanni Rotondo, it also owns and runs a retirement home for the elderly.
In addition, CSS owns 3 hospitality facilities where affordable accommodation is offered to hospitalized patients’ relatives who have to assist them; and another facility (Casa Zeni) where accommodation is offered free of charge to the parents of the little patients hospitalized in the oncology-hematology unit.
Moreover, the Foundation includes the Padre Pio Prayer Groups Centre, which was also founded by San Pio and coordinates the Padre Pio prayers groups throughout the world, according to the Founder’s wish that Prayers Groups live and testify the importance of prayer and pray for CSS.
Lastly, CSS publishes a monthly periodical and posts on the Foundation’s official channels on the web updates on its research and clinical activity and its spiritual activity and the teachings of the Founder.
The hospital offers assistance also to people from underdeveloped countries. 
Moreover, a free-of-charge shuttle service has been provided for many years to radiotherapy patients coming from Bari and surrounding cities (Southern Puglia).

THE CLINICAL ACTIVITY
CSS has around 756 beds, 38 medical and surgical inpatient units, 26 operating rooms, in addition to services, diagnostic and multi-specialist outpatient units.
In 2022, the hospital recorded over 30,000 hospitalizations and 870,000 outpatient performances. 
Regarding the advanced technological equipment, CSS has 1 "Da Vinci" surgical robot, 1 PET/CT device, 3 linear accelerators, 4 CT devices, 1 CT simulator for radiotherapy, 4 NMR equipment, 3 digital angiographs, 2 gamma cameras and a RIS/PACS system for the filmless management of the radiology department.
Furthermore, CSS hosts an Umbilical Cord Bank and a Human Milk Bank.
Recent Achievements
In addition to the many important activities carried out in CSS, 3 new units have been opened: 1. a new Emergency Room hosting an Observation and Assessment Ward; 2. an Hematopoietic Stem Cell Transplant Center. 3. an Sub-Intensive Geriatric Unit. 
CSS has also established a Stroke Unit, a Lung Unit, a Breast Unit, a Head and Neck Unit, and a Molecular Tumor Board to guarantee appropriate, quality and homogeneous procedures.
Future goals
Important technological investments have been planned for the years 2023-2025 in the following areas: oncology/nuclear medicine, diagnostic imaging, ICU, and surgery. 

THE RESEARCH ACTIVITY
The research activity is conducted in the Polyclinic, the ISBReMIT research center and at the Mendel Institute, for a total of 17 research groups.
Recent achievements
The consolidated experience of the staff working in CSS in the study of genetic diseases since 1991 and the continuous updating of technologies, instrumentation and genomics and post-genomics skills have made it possible to direct the research and clinical-assistance activity towards two complementary research lines: "personalized medicine - system biomedicine" and "regenerative medicine" based on the study of tumor stem cells and the use of normal stem cells.
The scientific fields in which the Institute is mostly involved in "personalized medicine" concern the identification of the genetic causes of rare diseases and the identification of diagnostic, prognostic and predictive markers in complex pathologies, including tumor pathologies. Regarding the identification of the genetic causes of rare diseases, we use the new next generation sequencing (NGS) technologies and the skills acquired by the bioinformatics unit, one of the first established at national level. In parallel, the Institute boasts a large collection of induced pluripotent stem cells (iPSCs), produced from patient fibroblasts, in which pathogenetic variants have been identified, and use the skills acquired in differentiating them into mature cells, in particular astrocytes, neurons and oligodendrocytes.
Regarding regenerative medicine, two important studies were conducted and concluded: a phase I trial on anti-Multiple Sclerosis therapy based on the use of human neural stem cells, approved by the Ministry of Health and the Italian Medicines Authority AIFA (EudraCT code 2015-004855-37); and a phase I/II trial on anti-glioma therapy with biological drugs (EudraCT code: 2016-001761-92). The results of these studies will published in prestigious international journals.
In 2015, the new ISBReMIT Regenerative Medicine Research Center was started. It is a cutting-edge structure in terms of conception and equipment in the field of translational medicine for genetic, degenerative and oncological diseases. The structure hosts, together with the highly technologically equipped laboratories, a cell factory and a laboratory for the production of biopharmaceuticals under Good Manufacturing Practice, i.e. for clinical use, including somatic stem cells and iPS, vectors for gene therapy and biomaterials.
It should be noted that CSS has recently become part of three Networks of the Italian Research Centers: since 2016 it has been an Ordinary Associate of Alleanza Contro il Cancro; since December 2018, of the National Research Network on Aging; and, finally, since March 2020 of the Neuroscience Network. Starting from 2022, CSS has been part of the European reference networks for rare and uncommon diseases (European Reference Networks - ERN), in particular ERN-SKIN on diseases of dermatological interest, and ERN ReCONNET on musculoskeletal diseases and pathologies of the connective tissue.
Researchers publish about 200 scientific articles in the most renowned journals (Science, New England Journal of Medicine, Nature Genetics) every year. They are engaged both as Principal Investigators and as partners in research projects in the biomedical field and ICT, obtaining funds from the EU (H2020 and FP7) and national or regional calls.
CSS is also a partner in Research and Innovation projects funded by private and public bodies, e.g. from the EU both under Horizon 2020 and Horizon Europe, in the field of digital transformation of healthcare. The main areas of involvement concern Assistive Robotics, Artificial Intelligence, Big Data generated by consumer devices, eHealth, Digital Therapies, the Internet of Things and Cybersecurity.
Future goals
Starting from the identification of the genetic causes of diseases, the goal is to develop advanced therapies to bring to the patient's bedside and tailored to him/her.
Furthermore, at the end of 2023, the phase II study "Neural Stem Cell Treatment for Amyotrophic Lateral Sclerosis: A multicenter, randomized placebo controlled and biological endpoints clinical Trial" (EudraCt 2018-002373-22) will be launched. This involves the use of neural stem cells on patients suffering from Amyotrophic Lateral Sclerosis.

CONCLUSION
Casa Sollievo della Sofferenza was born of the visionary mind of a poor friar, one of the most important, recent and internationally recognized and prayed Saints, Saint Pio of Pietrelcina, right after the II World War, in a poor corner of the Southern Italy of those times. 
CSS, by its Statutes, is a not-for-profit organization. All the good work that has been done until now for the sick has been possible thanks to the generosity of donors and to the public and private funds that have been collected through the hard work of the Foundation’s researchers and clinicians, thus contributing importantly to the care of citizens from Southern Italy and underdeveloped countries and to the world research.

Fondazione di Religione e di Culto Casa Sollievo della Sofferenza - Opera di San Pio da Pietrelcina

ConnectMyVariant's mission is to end hereditary disease by bringing families together.

ConnectMyVariant is an educational health-focused 501(c)3 nonprofit organization that supports individuals and families with hereditary disease in their early detection and prevention efforts. We provide unique value by leveraging our evidenced-based family connection protocols to help people identify other at-risk relatives and help those relatives access genetic testing so that they can get optimal medical care. ConnectMyVariant brings people with the same genetic risk together through our variant database and community engagement events to share experiences and find common ancestors. ConnectMyVariant also works to increase awareness of the benefits of family outreach among physicians, others who provide prevention care, and the broader genealogy community.
 
Our key activities are:

- Working with patients to implement personalized family outreach plans
- Interactive educational workshops about sharing information on inherited disease risk
- Variant specific family reunions to share stories and plan outreach to cousins
- Genealogy assistance to help connect individuals in variant groups
- Individual equity and inclusion grants for family and community outreach

Need and Impact:
When hereditary disease risk is known, family outreach has been proven to be the most effective and cost-effective intervention for early detection and prevention. This family outreach, also known as cascade testing, is recommended by multiple guidelines. Despite overwhelming evidence, family outreach assistance is not reimbursed by insurance or integrated into healthcare. Many people suffer and die from hereditary disease that could have been prevented or caught early.
 
We have shown that our strategies to encourage family outreach can act as a communication multiplier. Our pilot research at the University of Washington showed that this approach enhanced patient experience, was considered ethical, and was appreciated by newly identified relatives. Our approach is low-cost and is 25 to 50 times more effective than awareness and education interventions that target the general population.

Equity and Inclusion:
ConnectMyVariant is committed to being a leader for equity, diversity, and inclusion in hereditary disease prevention. ConnectMyVariant’s goal is to spread awareness among all individuals and families about inherited disease risk. All project staff, participants, and partners in ConnectMyVariant have an equal voice in developing innovative ways to improve hereditary disease outreach and prevention for all people. By fostering a diverse and inclusive community, we can provide knowledge and opportunities that have been historically inaccessible to millions of people.

ConnectMyVariant

Protecting children's brain development through salt iodization


Entering pregnancy with adequate iodine in the diet protects children's brain development and helps them to grow and learn better. The small amounts of iodine needed can be obtained by using iodized salt in cooking or in food products. It costs just 5 cents a year for a lifetime of protection.

Despite not being directly related to schools, removing this barrier to healthy development is one of the cheapest and easiest ways to support children's educational outcomes. 

IGN is only organization with a sole objective to protect the world from iodine deficiency.  The problem has never fully disappeared, and changing dietary patterns are causing deficiency to re-emerge, even in some of the world’s wealthiest countries.  

Without our work, the global progress achieved over the past few decades could disappear*.*  It would be a major loss to humanity to see this progress slip away when we know how to prevent it. It may be a humble intervention, requiring relatively small amounts of funding, but its impact is enormous.  Thanks to all of you for your past and future support for our work. 

Iodine Global Network

Delivering mobile-based rehabilitation programs to treat COPD, making treatment accessible in areas where it is currently lacking.

**Overview**
Respira Health is developing a free, mobile-based pulmonary rehabilitation program to close the treatment gap for chronic obstructive pulmonary disease (COPD) - India’s second leading cause of death. Incubated in March 2025 through Ambitious Impact’s Charity Entrepreneurship Program, we are in the early stages of building a scalable, cost-effective model for delivery across low-resource settings.

**The Problem**
COPD is the fourth leading cause of death globally, responsible for over 3 million deaths annually. Critically, 90% of these deaths occur in low- and middle-income countries (LMICs), where limited healthcare capacity and logistical challenges prevent patients from accessing effective treatment. In India, this treatment gap is especially pronounced, despite the availability of proven interventions.

**Our Solution**
Pulmonary rehabilitation (PR) is a well-established intervention combining strength and cardio exercises, breathing techniques, lifestyle support (e.g., smoking cessation), and psychological care. Research shows that just three PR sessions can reduce the risk of death by 9%. Digital delivery of PR via mobile phones or web platforms has been shown to be as effective as in-person programs, but at a fraction of the cost. Respira Health is adapting existing PR content into a mobile-first format accessible via widely used platforms like WhatsApp to ensure it reaches underserved COPD patients across India.

**Current Activities**
We are conducting scoping visits in Mumbai and Delhi from July - September 2025. Our objectives are to:

- Understand the burden of COPD and the broader healthcare landscape.
- Conduct needs assessments with healthcare workers and patients.
- Test key assumptions around digital platform usability, referral pathways, and patient adherence.
- Build relationships with potential collaborators for future pilot implementation.

**Future Plans**
Upon completion of our proof-of-concept phase, we will fundraise for a pilot launch. Our primary goal for Year 1 is to demonstrate uptake, engagement, and adherence in low-resource communities, paving the way for scale-up in 2026.

**Impact Potential**
Our intervention could provide millions of COPD patients with access to life-extending care currently out of reach. By leveraging digital tools, we aim to overcome traditional delivery barriers and radically expand access to pulmonary rehabilitation. We estimate that the average patient completing our program will gain over six months of healthy life. Based on our cost modelling, we anticipate averting a disability-adjusted life year (DALY) for just $20 - making our intervention potentially five times more cost-effective than GiveWell’s funding bar for highly cost-effective charities.

Respira Health

LifeStraw operates the Safe Water Fund, a 501(c)3 project, to support the provision of safe water where it is needed most.  

The Safe Water Fund operates as a 501(c)(3) project, supporting the implementation of long-term, sustainable safe water programs worldwide. We partner with grassroots organizations and local leaders to identify and reach communities and families most in need.

In addition to our retail-funded Give-Back program, the Safe Water Fund provides safe water during humanitarian emergencies and natural disasters. We also lead special initiatives in the cities where our employees live, including at our headquarters in Baltimore City, and participate in Giving Tuesday efforts each year.

**100% of donated funds go directly toward products and the distribution of safe water supplies. Vestergaard Frandsen, Inc. (d/b/a “LifeStraw”) does not profit from your donation.**

*The Safe Water Fund operates through a fiscal sponsorship with Players Philanthropy Fund, a Texas nonprofit recognized by the IRS as a tax-exempt public charity under Section 501(c)(3) of the Internal Revenue Code (Federal Tax ID: 27-6601178, ppf.org/pp). Contributions to the Safe Water Fund qualify as tax-deductible.*

Your contribution helps us bring safe drinking water to more families. 

Thank you for your support!

LifeStraw Safe Water Fund

Our School's global impact would not be possible without the crucial support of our community of committed donors and friends. 

The London School of Hygiene & Tropical Medicine (LSHTM) is renowned for its world-leading research, postgraduate studies and continuing education in public and global health.

With your help, we can increase the number of scholarships we are able to offer. We receive thousands of applications every year, with funding only available to support a small number. 

Our diverse student body is what makes our community so special. Each year, your support funds our LSHTM Fund Scholars, enabling exceptional students to study at our School. We receive thousands of applications every year, with funding only available to support a small number. Without support, many brilliant students like this year's LSHTM Fund Scholar, Judy Baariu (MSc Public Health for Development, 2023) would not have been able to study with us.

LSHTM has over 3,500 staff conducting research in more than 100 countries, with core hubs in London and at the MRC Units in The Gambia and Uganda. Our outstanding, diverse and committed staff make an impact where it is most needed - deploying research in real time in response to crises, developing innovative programmes for major health threats, or training the next generations of public and global health leaders and researchers.

We help shape health policy and translate research findings into tangible impact. We are uniquely placed to lead on transformative approaches to global health and have 120 years of experience tackling big challenges. We are focused on finding new solutions to complex problems and acting upon this knowledge.

We work in collaboration with friends, partners, and supporters to achieve large-scale, long-term impact. Researchers at LSHTM explore all aspects of health challenges, from fundamental laboratory science to policy appraisal and analysis, encompassing statistical, clinical, laboratory, epidemiological and social science research globally.

Our aim is to build strong and dynamic leadership, push the frontiers of knowledge and make an impact where it is most needed. Philanthropy helps us achieve our mission; to improve health and health equity worldwide; working in partnership to achieve excellence in public and global health research, education and translation of knowledge into policy and practice.

London School of Hygiene & Tropical Medicine

One of GiveWell's top charities for the past several years, AMF provides anti-malarial bednets to people in need. 

From Givewell: 
What do they do? AMF (againstmalaria.com) provides funding for long-lasting insecticide-treated net (LLIN) distributions (for protection against malaria) in developing countries. (More)

Does it work? There is strong evidence that distributing LLINs reduces child mortality and malaria cases. AMF conducts post-distribution surveys of completed distributions to determine whether LLINs have reached their intended destinations and how long they remain in good condition. AMF's post-distribution surveys have generally found positive results but have some methodological limitations. (More)

What do you get for your dollar? We estimate that the cost to purchase and distribute an AMF-funded net is $4.95, or $4.65 excluding in-kind contributions from governments. The numbers of deaths averted and other benefits of distributing LLINs are a function of a number of difficult-to-estimate factors, which we discuss in detail below. (More)

Is there room for more funding? We believe that AMF is likely to be constrained by funding. We estimate that AMF could use up to an additional $37.8 million to support LLIN distributions that will occur between now and late 2023. 

AMF is recommended because of its:

Focus on a program with excellent evidence of effectiveness and cost-effectiveness.
Processes for ensuring that nets reach their intended recipients and monitoring whether they remain in homes and in good condition over the long-term.
Room for more funding – we believe AMF will be able to use additional funds to deliver additional nets.
Transparency – AMF shares significant information about its work with us and we are able to closely follow and understand its work.

The Against Malaria Foundation

Helen Keller, our co-founder, envisioned a world without barriers to human potential. We are continuing her work.


Helen Keller, our co-founder, envisioned a world without barriers to human potential. Guided by her fierce optimism, we have been working on the front lines of health and well-being for more than 100 years. We deliver life-changing health care to vulnerable families in places where the need is great, but access is limited. Our proven, science-based programs empower people to create opportunities in their own lives.


Helen Keller International

1151123349

We are a nonprofit helping organizations raise more for their missions, so we rely on the generosity of donors like you.

Choose a donation for Every.org

148788709

1578280819

1873740264

188270313

2052641908

2088874155

We are a nonprofit, so instead of charging fees we rely on the generosity of donors like you.

.css-1wjgqn{display:inline-block;--textSize:1.5rem;--lineHeight:1.7999999999999998rem;line-height:var(--lineHeight);font-size:var(--textSize);width:100%;}Disease Prevention

Mersal Foundation for Charity and Development

Mersal Foundation for Charity and Development

Mersal Foundation for Charity and Development

Mersal Foundation for Charity and Development

Mersal Foundation for Charity and Development

Mersal Foundation for Charity and Development

Disease Prevention